Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. The Company's subsidiary, Harvest Medicine provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by subaru1ion May 31, 2023 1:29am
189 Views
Post# 35471678

LABS mentioned 'patent threats' in the more recent past and

LABS mentioned 'patent threats' in the more recent past and

seeing what they have done so far via the FDA, those actions could easily be applied to JAZZ Pharma obtaining an FDA approved but YET very unique CBD formulation that would be used in Epidiolex with over 100 compounds identified.  That means the only way a competitor could copy Epidiolex is by getting that exact formulation of CBD extraction from LABS.   Getting the groundwork ready well before the patents on Epidiolex expire and the patent renewals by JAZZ for Epidiolex references the FDA approved formulation from LABS.  

To prevent LABS from selling that CBD formulation to a competitor of JAZZ, then JAZZ simply signs an exclusive deal with LABS to be the only supplier of that CBD formulation and only to JAZZ.  

Now give that some very serious thought because LABS has already name dropped Epidiolex over the course of a minimum of 2 conference calls.   

That could also explain besides the submission of their CBD to the FDA, now FDA approved along with the FDA site visit in Barrie, that LABS also submitted the ANDA to the FDA, both submissions go hand in hand to become the sole supplier to JAZZ for Epidiolex.  

Please, don't ask me what got me up at this time of night to make this post because if I told you, I am still wondering, can you handle the Truth π?  And on that note, Roscomos, did you do an approximate calculation yet of how many giga Joules of energy that bright light streak across the SOHO image of the Sun would have needed to dissipate that much visible light alone, not vectoring in the velocity component.  

 

<< Previous
Bullboard Posts
Next >>